Psilocybin, the active compound in certain mushrooms used by Aztec Indians in religious and healing rituals, was identified and synthesized in the mid-20th century after a search sparked by a 16th-century Spanish friar's writings. Recent FDA-approved clinical studies suggest potential value for psilocybin-assisted psychotherapy in treating depression, anxiety, and certain addictions, though larger studies are needed to validate these early findings.
A new compound, gymnopilin K, along with four known compounds, was isolated from the hallucinogenic mushroom Gymnopilus spectabilis, collected in Korea. The chloroform-soluble fraction of the mushroom extract showed significant cytotoxicity against A549, SK-OV-3, SK-MEL-2, and HCT-15 human tumor cell lines in a sulforhodamine B bioassay. The structure of gymnopilin K was determined using NMR spectroscopy and chemical reactions. This work describes the isolation and structural elucidation of these compounds and reports their cytotoxic activities.